Anal cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Anal cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab with Standard Chemoradiation for Patients with Advanced Anal Cancer https://clinicaltrials.eu/trial/study-of-pembrolizumab-with-standard-chemoradiation-for-patients-with-advanced-anal-cancer/ Wed, 29 Apr 2026 15:03:38 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-with-standard-chemoradiation-for-patients-with-advanced-anal-cancer/ This clinical trial is focused on studying a type of cancer called anal cancer, specifically in its advanced stages. The treatment being tested is a medication known as pembrolizumab, which is also referred to as a checkpoint inhibitor. This medication is used in combination with a standard treatment method called chemoradiation, which involves using both chemotherapy and radiation therapy to treat cancer. The purpose of the study is to evaluate the safety and how well patients can tolerate different schedules of pembrolizumab when used alongside standard chemoradiation in patients with advanced anal cancer.

Participants in the study will receive pembrolizumab through an infusion, which means the medication is given directly into the bloodstream. The study will explore two different schedules for administering pembrolizumab to see which is more effective and better tolerated by patients. Throughout the study, researchers will monitor participants for any side effects and how well they adhere to the treatment plan. The study will also assess how feasible it is to combine pembrolizumab with standard chemoradiation and will track the overall response of the cancer to the treatment over time.

In addition to monitoring the safety and effectiveness of the treatment, the study will also look at how the cancer responds to the treatment using imaging techniques like MRI (Magnetic Resonance Imaging). Researchers will evaluate changes in the cancer at different points during and after the treatment. Patient-reported outcomes will also be collected to understand the impact of the treatment on symptoms and quality of life. The study aims to provide valuable information on the potential benefits of using pembrolizumab in combination with standard treatments for advanced anal cancer.

]]> Study of TG4001 and Avelumab for Patients with Advanced HPV-16 Positive Cancers https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-of-tg4001-and-avelumab-for-patients-with-advanced-hpv-16-positive-cancers/ This clinical trial is focused on studying certain types of cancers that are linked to a virus called Human Papillomavirus (HPV), specifically the type known as HPV-16. The cancers being studied include those that can occur in areas such as the head and neck, cervix, vulva, vagina, penis, and anus. The study is testing a combination of two treatments: avelumab, which is a type of cancer immunotherapy, and TG4001, which is another form of immunotherapy designed to help the body’s immune system fight cancer cells.

The purpose of the study is to evaluate how safe and effective these treatments are when used together in patients with advanced stages of these HPV-16 related cancers. The study will be conducted in two phases. In the first phase, the focus will be on understanding the safety and how well patients tolerate the combination of avelumab and TG4001. In the second phase, the study will look at how well the combination works in terms of slowing down the progression of the cancer compared to using avelumab alone.

Participants in the study will receive the treatments through injections or infusions, and their health will be monitored over time to see how the cancer responds to the treatment. The study aims to provide valuable information on whether this combination of treatments can offer a new option for patients with these types of cancers.

]]> Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers https://clinicaltrials.eu/trial/study-on-pelareorep-and-atezolizumab-for-patients-with-advanced-or-metastatic-gastrointestinal-cancers/ Wed, 29 Apr 2026 14:23:15 +0000 https://clinicaltrials.eu/trial/study-on-pelareorep-and-atezolizumab-for-patients-with-advanced-or-metastatic-gastrointestinal-cancers/ This clinical trial is focused on studying advanced or metastatic gastrointestinal cancers, which are cancers that affect the digestive system. The study is exploring the effects of two treatments: pelareorep and atezolizumab. Pelareorep is also known by other names such as Reovirus Type 3 Dearing, and atezolizumab is sometimes referred to by its code name, RO5541267. Both medications are given as a solution for infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate the safety and effectiveness of combining pelareorep and atezolizumab with standard chemotherapy treatments. Participants will receive these treatments and be monitored for their response to the therapy. The study will assess how well the combination of these drugs works in treating the cancer and how well patients tolerate the treatment. The study will also look at the overall response rate, which measures how the cancer responds to the treatment, and the disease control rate, which indicates how well the treatment keeps the cancer from growing or spreading.

Throughout the study, participants will undergo regular assessments to monitor their health and the effects of the treatment. These assessments will include checking for any side effects and measuring the size of the cancer to see how it responds to the treatment. The study aims to provide valuable information on the potential benefits of using pelareorep and atezolizumab together with standard chemotherapy for treating advanced gastrointestinal cancers.

]]>